Investors
Overview

Investors Overview

Company Profile

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B.

Recent/Upcoming Events
Jan 04 - Jan 06, 2024

Presentation: Pemvidutide-Induced Liver Fat Reduction in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease Correlates with Improvements in Non-Invasive Markers of Inflammation and Fibrosis: Results of a 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (abstract #51)

Authors: Stephen A. Harrison, Shaheen Tomah, John J. Suschak, Jonathan Kasper, M. Scot Roberts, M. Scott Harris, Sarah K. Browne

Nov 13, 2023 at 1:00 PM EST

Late-Breaking Poster Presentation: Pemvidutide-induced liver fat reduction in subjects with non-alcoholic fatty liver disease correlate with improvements in non-invasive markers of inflammation and fibrosis: Results of a 24-week multicenter, randomized, double-blind, placebo-controlled trial

Presenter: Dr. Stephen Harrison, Medical Director, Pinnacle Research, and Adjunct Professor of Medicine, Oxford University

btn Events

 

Investor Contact

Richard Eisenstadt
Chief Financial Officer

Email: reisenstadt@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe